

# Performance monitoring matrix for KP sites in Côte d'Ivoire



Authors: Gneki Ble Cyprien RABE<sup>1</sup>, Adigatta TRAORE<sup>1</sup>, Marcelline KOYE<sup>1</sup>, Daniel Koné ZANA<sup>1</sup>, Ferima DEMBELE<sup>2</sup>, Inza BAMBA<sup>1</sup>, Evelyne Patrice OBODOU<sup>3</sup>, Abdramane DIABAGATE<sup>1</sup>, Mathurin KOUADJALE<sup>1</sup>, Eboi EHUI<sup>1</sup>  
 1. National AIDS Control Program (PNLS), 2. DGS, 3. Global Fund

## BACKGROUND / INTRODUCTION

- Interventions targeting key populations (KPs) are a priority in the 2021-2026 National HIV Strategic Plan. However, the performance of sites dedicated to KPs varies across regions and partners.
- To improve monitoring and data quality, PNLS, with support from the Global Fund, has developed a national performance monitoring matrix to regularly evaluate sites.
- This national tool for the continuous improvement of HIV service quality for KPS aims to strengthen strategic decision-making and planning based on evidence.

**Key objective: Plan and monitor interventions targeting key populations to ensure the quality and continuity of services.**

## METHODS

This tool, designed with eight (08) tabs, allows you to:

- Monitor program targets by type of KP
- Measure the performance of prevention, testing, and treatment cascades
- Monitor essential inputs (condoms, lubricant gel, testing supplies, and STI kits) at KPS sites

## RESULTS

### Performance

**Prevention Performance:**

- Monitoring of prevention activities and measurement of the level of achievement of targets set each quarter

**Screening Performance:**

- Evaluation of the capacity of sites to offer HIV screening per quarter and per key population type

**Treatment Performance:**

- Monitoring the initiation of treatment for PLHIV KPs and their retention in care by type of key population and by quarter

| MSM performance prevention                 |         |         |         |         |         | TS prevention performance                  |         |         |         |         |         |
|--------------------------------------------|---------|---------|---------|---------|---------|--------------------------------------------|---------|---------|---------|---------|---------|
| Indicators                                 | Q1      | Q2      | Q3      | Q4      | Total   | Indicators                                 | Q1      | Q2      | Q3      | Q4      | Total   |
| P1 Coverage in male condoms                | 0.12    | 0.10    | 0.06    | 0.22    | 0.50    | P1 Coverage in male condoms                | 25.31   | 25.13   | 11.69   | 43.28   | 105.41  |
| P2 Coverage in female condoms              | 0.00    | 0.00    | 0       | 0       | 0.00    | P2 Coverage in female condoms              | 25.31   | 25.13   | 11.69   | 43.28   | 105.41  |
| P3 Lubricant gel coverage                  | 0.12    | 0.10    | 0.06    | 0.22    | 0.50    | P3 Lubricating gel coverage                | 25.31   | 25.13   | 11.69   | 43.28   | 105.41  |
| P4 CCC coverage                            | 28.43   | 23.86   | 13.71   | 53.30   | 53.30   | P4 CCC coverage                            | 25.31   | 25.13   | 11.69   | 43.28   | 105.41  |
| P5 Promotional coverage of PrEP            | 28.43   | 23.86   | 13.71   | 53.30   | 119.29  | P5 Promotional coverage of PrEP            | 25.31   | 25.13   | 11.69   | 43.28   | 105.41  |
| P6 Coverage of PrEP eligibility assessment | 0.00    | 0.00    | 7.69    | 101.94  | 0.00    | P6 Coverage of PrEP eligibility assessment | 0.00    | 0.00    | 1.52    | 105.53  | 0.00    |
| P7 Coverage of PrEP initiation             | #DIV/0! | #DIV/0! | 100.00  | 100.00  | #DIV/0! | P7 Coverage of PrEP initiation             | #DIV/0! | #DIV/0! | 100.00  | 100.00  | #DIV/0! |
| P8 Continuous PrEP coverage                | #DIV/0! | #DIV/0! | 100.00  | 98.13   | #DIV/0! | P8 Continuous PrEP coverage                | #DIV/0! | #DIV/0! | 100.00  | 99.60   | #DIV/0! |
| P9 Treatment coverage for STIs             | #DIV/0! | #DIV/0! | #DIV/0! | #DIV/0! | #DIV/0! | P9 Treatment coverage for STIs             | #DIV/0! | #DIV/0! | #DIV/0! | #DIV/0! | #DIV/0! |

### Matrix structure

**Target**  
Presents the programmatic objectives or targets set by donors

**Site data**  
Effective implementation by site according to the type of key population

**RESULTS**  
The matrix comprises three (03) performance areas visualized through a dashboard:

- (≥85%) High performance
- (75–85%) Acceptable
- (<75%) Needs improvement


### Use and process



**Availability of inputs:**

- Monitor availability and logistics management essential for prevention and screening at sites

### Input monitoring



### Cascades

**Prevention cascade:**

- Allows you to view the chain of results of prevention interventions.

**Treatment cascade:**

- Ensures follow-up of the continuum of care and treatment for KPs living with HIV

## ADDED VALUE

- A single, harmonized tool for all KPS partners.
- Enables management based on data rather than perception.
- Stimulates positive competition between sites and the sharing of best practices.
- Feeds into the PNLS quarterly performance reviews

## OUTLOOK

- Ongoing training for site managers in interpreting the matrix.
- Production of an annual national report on the performance of KPS sites.
- Extension of the matrix to other priority populations.

## CONCLUSION

- Strategic decision-making tool** facilitating planning, resource reallocation, and strengthening of weak sites.
- Analysis of gaps and corrective actions** to improve the implementation of interventions targeting key populations.



**POUSSONS POUR L'ÉGALITÉ**

WWW.PNLSCI.COM

CQUIN 9th Annual Meeting | Delivering Differently: Prioritize. Adapt. Sustain  
 November 17-21, 2025 | Durban